Unknown

Dataset Information

0

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections.


ABSTRACT:

Background

Thresholds for SARS-CoV-2 antibody assays have typically been determined using samples from symptomatic, often hospitalised, patients. In this setting the sensitivity and specificity of the best performing assays can both exceed 98%. However, antibody assay performance following mild infection is less clear.

Methods

We assessed quantitative IgG responses in a cohort of healthcare workers in Oxford, UK, with a high pre-test probability of Covid-19, in particular the 991/11,475(8.6%) who reported loss of smell/taste. We use anosmia/ageusia and other risk factors as probes for Covid-19 infection potentially undiagnosed by immunoassays by investigating their relationship with antibody readings either side of assay thresholds.

Results

The proportion of healthcare workers reporting anosmia/ageusia increased at antibody readings below diagnostic thresholds using an in-house ELISA (n = 9324) and the Abbott Architect chemiluminescent microparticle immunoassay (CMIA; n = 11,324): 426/906 (47%) reported anosmia/ageusia with a positive ELISA, 59/449 (13.1%) with high-negative and 326/7969 (4.1%) with low-negative readings. Similarly, by CMIA, 518/1093 (47.4%) with a positive result reported anosmia/ageusia, 106/686 (15.5%) with a high-negative and 358/9563 (3.7%) with a low-negative result. Adjusting for the proportion of staff reporting anosmia/ageusia suggests the sensitivity of both assays in mild infection is lower than previously reported: Oxford ELISA 89.8% (95%CI 86.6-92.8%) and Abbott CMIA 79.3% (75.9-82.7%).

Conclusion

Following mild SARS-CoV-2 infection 10-30% of individuals may have negative immunoassay results. While lowered diagnostic thresholds may result in unacceptable specificity, our findings have implications for epidemiological analyses and result interpretation in individuals with a high pre-test probability. Samples from mild PCR-confirmed infections should be included in SARS-CoV-2 immunoassay evaluations.

SUBMITTER: Eyre DW 

PROVIDER: S-EPMC7889711 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7444492 | biostudies-literature
| S-EPMC8092742 | biostudies-literature
| S-EPMC7263247 | biostudies-literature
| S-EPMC10622572 | biostudies-literature
| S-EPMC10952984 | biostudies-literature
| S-EPMC9263831 | biostudies-literature
| S-EPMC7577439 | biostudies-literature
| S-EPMC7395943 | biostudies-literature
| S-EPMC8320896 | biostudies-literature
| S-EPMC8622816 | biostudies-literature